Cannabix develops marijuana breathalyzers to give law enforcement and employers a tool to improve public safety
Cannabix Technologies Inc.
VANCOUVER, British Columbia, May 09, 2022 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana-based breathalyzers for law enforcement Order and Workplace Reporting successfully tested an additional version of its FAIMS technology for the detection of ∆9-tetrahydrocannabinol (“THC”) and related analytes in human breath in an independent experimental study . The study showed an excellent correlation between breath samples collected and analyzed with Cannabix equipment and THC levels in blood plasma. The company’s portable breath collection unit (“BCU”, Fig. 1) and new laboratory “MS Breath Sampler” (Fig. 2) have been used together to provide a revolutionary new drug detection method that complements reference mass spectrometry. (MS), and has the potential to significantly reduce analysis times and operating costs in the laboratory, while maintaining sensitive and accurate results. The company has developed a unique breath analysis system capable of sampling breath for low volatility analytes, such as THC, and can be completed in seconds, with no sample preparation required.
This new system, developed by Cannabix scientists and engineers, was recently tested in an independent study conducted by pioneering scientist Dr. Phillip Olla of Audacia Bioscience in Ontario. Dr. Olla is one of the few scientists in the world to have performed THC analyzes in blood and breath.
THC in Breath and Blood Data
The experimental study included 6 subjects with a 60%-40% between men and women with an average age of 23 years. Breath and blood samples were collected simultaneously at baseline (one time before smoking cannabis) and additional time points (after smoking cannabis) up to 1 hour and 40 minutes after smoking (it is appropriate to note that Cannabix was able to detect and confirm THC on the breath using the same material up to 4 hours after smoking in recent lab tests). Breath samples were taken with the Cannabix BCU and analyzed using the Cannabix Mass Spectrometer (MS) Breath Sampler coupled with the Thermo TSQ Quantum Ultra MS. THC fragments were analyzed using Thermo Xcalibur software and areas under the chromatogram curves (AUC) were determined using the detection function of the software. Blood serum samples were analyzed at the Analytical Facility for Bioactive Molecules at the Hospital for Sick Children (Toronto, ON, Canada) using LC/MS/MS according to conventional standard operating procedures.
The resulting data (see Fig. 3 below) provides an excellent correlation between human breath samples collected and analyzed with Cannabix equipment and plasma THC levels. Additionally, the data from this experimental study supports the literature by showing the same trends in THC metabolism, and that blood and breath levels of THC over time are correlated with a high degree of accuracy – within one or two hours. after smoking (Fig. 4). Readers should note that blood is currently the standard measurement for law enforcement, toxicologists, and evidence used in court. The BCU is also used with Cannabix’s portable FAIMS THC detection unit.
Cannabix Senior Analytical Chemist Dr Jared Boock said: “This study demonstrates the ability of the Cannabix Breath Analysis System to easily and quickly collect breath samples in the field and correlate it with levels of THC in the blood. Law enforcement and toxicologists rely on the results of reference mass spectrometry to confirm the presence of drugs in the blood. We have developed a truly revolutionary breath analysis tool capable of sampling breath for THC, in seconds, with no sample preparation required. Additionally, we were able to store, ship and analyze samples for up to 40 hours after they were collected in the field.
A photo accompanying this ad is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/072dd794-1bf0-4db4-bb7e-5f3cd789038c
(1) “Blood cannabinoids. I. THC uptake and formation of 11-OH-THC and THCCOOH during and after smoking marijuana,” Journal of Analytic Toxicology, Vol. 16:276-282 (1992).
(2) The data presented in FIG. 4 were adapted from a historical study (1). Corresponding time points after smoking were selected to highlight the correlation between plasma THC levels between studies. For the complete data and the original graph, please refer to the original publication.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug screening devices that will detect THC – the psychoactive component of marijuana that causes deficiency using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better correlates with impairment. Cannabix devices are in advanced prototype and preclinical testing.
We’re looking for Safe Harbor.
On behalf of the Board of Directors
Cannabix Technologies Inc.
For more information, contact the Company at firstname.lastname@example.org
The CSE has not reviewed and accepts no responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information may include, but is not limited to, statements based on current expectations involving a number of risks and uncertainties and are not guarantees of the future performance of the Company, such as the eventual development of a or more commercial products or prototypes, a successful trial or pilot project. company technologies, no guarantee that commercial sales of any kind will actually materialize; there can be no assurance that the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks related to the protection of proprietary technology; (iii) the Company’s ability to obtain financing; (iv) the Company’s ability to develop and market its future product; and (v) risks regarding government regulation, managing and sustaining growth, the effect of adverse publicity, litigation, competition and other factors that may be identified from time to time in public announcements and the documents filed by the Company. There can be no assurance that its development of marijuana breathalyzer technology will provide any benefit to the Company, and there can be no assurance that any new products offered will be built, pass beta testing or clinical trials. There can be no assurance that existing “patent pending” technologies licensed by the Company will receive patent status with regulatory authorities. The Company does not currently sell commercial breathalyzers. Actual results and future events could differ materially from those anticipated in this information. This written and oral forward-looking information and all subsequent forward-looking information is based on management’s estimates and opinions as of the dates it is made and is expressly qualified in its entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.